Risultati per: Acne vulgaris: trattamento farmacologico

Tor Vergata è capofila come numero di interventi eseguiti

This cross-sectional study investigates the structural validity, internal consistency, and construct validity of the DermSat-7 questionnaire, which measures treatment satisfaction in patients with acne.

This survey study explores the degree of stigma toward individuals with acne and whether these attitudes vary based on characteristics of the individuals with acne or of the survey participants.

Objective
This study aims to estimate the cost-effectiveness of oral spironolactone plus routine topical treatment compared with routine topical treatment alone for persistent acne in adult women from a British NHS perspective over 24 weeks.

Design
Economic evaluation undertaken alongside a pragmatic, parallel, double-blind, randomised trial.

Setting
Primary and secondary healthcare, community and social media advertising.

Participants
Women ≥18 years with persistent facial acne judged to warrant oral antibiotic treatment.

Interventions
Participants were randomised 1:1 to 50 mg/day spironolactone (increasing to 100 mg/day after 6 weeks) or matched placebo until week 24. Participants in both groups could continue topical treatment.

Main outcome measures
Cost-utility analysis assessed incremental cost per quality-adjusted life year (QALY) using the EQ-5D-5L. Cost-effectiveness analysis estimated incremental cost per unit change on the Acne-QoL symptom subscale. Adjusted analysis included randomisation stratification variables (centre, baseline severity (investigator’s global assessment, IGA

This systematic review and meta-analysis analyzes the risk of acne associated with Janus kinase (JAK) inhibitors across published phase 2 and 3 placebo-controlled randomized clinical trials of JAK inhibitors.

This JAMA Dermatology Patient Page discusses isotretinoin for treatment of acne.

This systematic review evaluates the data behind the use of oral nutraceuticals in the treatment of patients with acne vulgaris.